Inverted papilloma of the urinary bladder: A molecular genetic appraisal

Modern Pathology

Volumn 19, Issue 10, 2006, Pages 1289-1294

  Sung, Ming Tse ^a,b   Eble, John N ^a   Wang, Mingsheng ^a   Tan, Puay Hoon ^c   Lopez Beltran, Antonio ^d   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Clonality; Inverted papilloma; Loss of heterogosity; Neoplasia; Urinary bladder; X chromosome inactivation

Indexed keywords

ARTICLE; BLADDER TUMOR; CHROMOSOME 17P; CHROMOSOME 3P; CHROMOSOME 9P; CHROMOSOME 9Q; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; INVERTED PAPILLOMA; MALE; MICROSATELLITE MARKER; MOLECULAR GENETICS; POLYMORPHIC LOCUS; PRIORITY JOURNAL; X CHROMOSOME; X CHROMOSOME INACTIVATION;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; PAPILLOMA, INVERTED; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM; X CHROMOSOME INACTIVATION;

EID: 33748872729     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800667     Document Type: Article

References (39)

1. Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon, 2004, pp 114-115.
2. Asano K, Miki J, Maeda S, et al. Clinical studies on inverted papilloma of the urinary tract: report of 48 cases and review of the literature. J Urol 2003;170:1209-1212.
3. Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol 2004;35:1499-1504.
4. Cheon J, Kim HK, Kim JJ, et al. Malignant inverted papilloma of the urinary bladder: the histopathological aspect of malignant potential of inverted papilloma. J Korean Med Sci 1995;10:103-110.
5. Cheville JC, Wu K, Sebo TJ, et al. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma? Cancer 2000;88:632-636.
6. Lazarevic B, Garret R. Inverted papilloma and papillary transitional cell carcinoma of urinary bladder: report of four cases of inverted papilloma, one showing papillary malignant transformation and review of the literature. Cancer 1978;42:1904-1911.
7. Renfer LG, Kelley J, Belville WD. Inverted papilloma of the urinary tract: histogenesis, recurrence and associated malignancy. J Urol 1988;140:832-834.
8. Stein BS, Rosen S, Kendall AR. The association of inverted papilloma and transitional cell carcinoma of the urothelium. J Urol 1984;131:751-752.
9. Urakami S, Igawa M, Shirakawa H, et al. Biological characteristics of inverted papilloma of the urinary bladder. Br J Urol 1996;77:55-60.
10. Witjes JA, van Balken MR, van de Kaa CA. The prognostic value of a primary inverted papilloma of the urinary tract. J Urol 1997;158:1500-1505.
11. Baud E, Catilina P, Boiteux JP, et al. Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion. Int J Cancer 1998;77:821-824.
12. Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999;18:1185-1196.
13. Keen AJ, Knowles MA. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 1994;9:2083-2088.
14. Louhelainen J, Wijkstrom H, Hemminki K. Multiple regions with allelic loss at chromosome 3 in superficial multifocal bladder tumors. Int J Oncol 2001;18: 203-210.
15. Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome 9 in human bladder cancer. Cancer Res 1993;53:4066-4070.
16. Orlow I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995;87:1524-1529.
17. Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998;26:223-233.
18. Primdahl H, von der Maase H, Christensen M, et al. Allelic deletions of cell growth regulators during progression of bladder cancer. Cancer Res 2000;60: 6623-6629.
19. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-709.
20. Brandli DW, Ulbright TM, Foster RS, et al. Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res 2003;63:6063-6068.
21. Cheng L, MacLennan GT, Zhang S, et al. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer 2004;101: 183-188.
22. Kernek KM, Ulbright TM, Zhang S, et al. Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol 2003;163:2477-2484.
23. Paterson RF, Ulbright TM, MacLennan GT, et al. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer 2003;98:1830-1836.
24. Uchida A, Tachibana M, Miyakawa A, et al. Microsatellite analysis in multiple chromosomal regions as a prognostic indicator of primary bladder cancer. Urol Res 2000;28:297-303.
25. Cheng L, Shan A, Cheville JC, et al. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res 1998;58:389-391.
26. Gu J, Roth LM, Younger C, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001;93:1147-1152.
27. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90: 233-237.
28. Cheng L, Gu J, Eble JN, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. Am J Surg Pathol 2001;25:1231-1236.
29. Katona TM, Jones TD, Wang M, et al. Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancreatic axis. Cancer Res 2006;66:4936-4942.
30. McCarthy RP, Wang M, Jones TD, et al. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res 2006;12:2414-2418.
31. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and co-existing urothelial carcinoma. Am J Pathol 2005;166: 1533-1539.
32. Cheng CW, Chan LW, Chan CK, et al. Is surveillance necessary for inverted papilloma in the urinary bladder and urethra? Aust NZ J Surg 2005;75:213-217.
33. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol 1997;21:1057-1068.
34. Junker K, Boerner D, Schulze W, et al. Analysis of genetic alterations in normal bladder urothelium. Urology 2003;62:1134-1138.
35. Chow NH, Carins P, Eisenberger CF, et al. Papillary urothelial hperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000;89: 514-518.
36. Cheng L, Darson M, Cheville JC, et al. Urothelial papilloma of the bladder: clinical and biologic implications. Cancer 1999;86:2098-2101.
37. Magi-Galluzzi C, Epstein JI. Urothelial papilloma of the bladder. A review of 34 de novo cases. Am J Surg Pathol 2004;28:1615-1620.
38. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
39. Vogelstein B, Fearon ER, Hamilton SR, et al. Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res 1987;47:4806-4813.